MBX Insider Trading Activity and SEC Form 4 Filings
MBX insider trading summary
Over the past 12 months, insiders at MBX Biosciences, Inc. (MBX) reported 6 sales worth $2.8M by 2 insiders and 1 open-market purchase worth $526K by 1 insider on SEC Form 4. Net insider selling was $2.2M.
Latest MBX insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Nov 4, 2026 | Salomon Azoulay | Chief Medical Officer | Sell | $20K (373 @ $53.96) |
| Aug 4, 2026 | Salomon Azoulay | Chief Medical Officer | Sell | $24K (370 @ $65.77) |
| May 8, 2026 | Salomon Azoulay | Chief Medical Officer | Sell | $575K (15,003 @ $38.30) |
| May 8, 2026 | Salomon Azoulay | Chief Medical Officer | Sell | $2.1M (55,000 @ $38.38) |
| May 6, 2026 | Salomon Azoulay | Chief Medical Officer | Sell | $7K (231 @ $29.54) |
| May 6, 2026 | P. Kent Hawryluk | President & CEO | Sell | $18K (607 @ $29.54) |
| Mar 13, 2026 | P. Kent Hawryluk | President & CEO | Buy | $526K (18,500 @ $28.41) |
| Oct 20, 2025 | P. Kent Hawryluk | President & CEO | Buy | $273K (20,000 @ $13.64) |
| Oct 17, 2025 | Steven L. Hoerter | Insider | Buy | $265K (20,000 @ $13.25) |
| Sep 26, 2025 | Patrick J Heron | Insider | Buy | $12.0M (666,666 @ $18.00) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.